Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011104337 - HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

Publication Number WO/2011/104337
Publication Date 01.09.2011
International Application No. PCT/EP2011/052810
International Filing Date 25.02.2011
IPC
C07D 495/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 519/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
A61K 31/519 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/5355 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5355Non-condensed oxazines containing further heterocyclic rings
A61K 31/55 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 3/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
Applicants
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE]/[DE] (AllExceptUS)
  • LEHMANN-LINTZ, Thorsten [DE]/[DE] (UsOnly)
  • KLEY, Joerg [DE]/[DE] (UsOnly)
  • REDEMANN, Norbert [DE]/[DE] (UsOnly)
  • SAUER, Achim [DE]/[DE] (UsOnly)
  • THOMAS, Leo [DE]/[DE] (UsOnly)
  • WIEDENMAYER, Dieter [DE]/[DE] (UsOnly)
  • AUSTEN, Matthias [DE]/[DE] (UsOnly)
  • DANILEWICZ, John [GB]/[GB] (UsOnly)
  • SCHNEIDER, Martin [DE]/[DE] (UsOnly)
  • SCHREITER, Kay [DE]/[DE] (UsOnly)
  • BLACK, Phillip [GB]/[GB] (UsOnly)
  • BLACKABY, Wesley [GB]/[GB] (UsOnly)
  • LINNEY, Ian [GB]/[GB] (UsOnly)
Inventors
  • LEHMANN-LINTZ, Thorsten
  • KLEY, Joerg
  • REDEMANN, Norbert
  • SAUER, Achim
  • THOMAS, Leo
  • WIEDENMAYER, Dieter
  • AUSTEN, Matthias
  • DANILEWICZ, John
  • SCHNEIDER, Martin
  • SCHREITER, Kay
  • BLACK, Phillip
  • BLACKABY, Wesley
  • LINNEY, Ian
Agents
  • HAMMANN, Heinz
Priority Data
10154925.126.02.2010EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
(FR) THIÉNOPYRIMIDINES CONTENANT UN GROUPE HÉTÉROCYCLOALKYLE POUR DES COMPOSITIONS PHARMACEUTIQUES
Abstract
(EN) The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
(FR) La présente invention porte sur de nouvelles compositions pharmaceutiques comprenant des composés thiénopyrimidines. De plus, la présente invention porte sur l'utilisation des composés thiénopyrimidines de l'invention pour la production de compositions pharmaceutiques pour la prophylaxie et/ou le traitement de maladies qui peuvent être influencées par l'inhibition de l'activité de kinase de Mnk1 et/ou Mnk2 (Mnk2a ou Mnk2b) et/ou de variantes de celles-ci.
Latest bibliographic data on file with the International Bureau